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Abstract: With its vast amount of uncharacterized and characterized T cell epitopes 
available for activating CD4+ T helper and CD8+ cytotoxic lymphocytes simultaneously, 
whole tumor antigen represents an attractive alternative source of antigens as compared to 
tumor-derived peptides and full-length recombinant tumor proteins for dendritic cell  
(DC)-based immunotherapy. Unlike defined tumor-derived peptides and proteins, whole tumor 
lysate therapy is applicable to all patients regardless of their HLA type. DCs are essentially 
the master regulators of immune response, and are the most potent antigen-presenting cell 
population for priming and activating naïve T cells to target tumors. Because of these unique 
properties, numerous DC-based immunotherapies have been initiated in the clinics. In this 
review, we describe the different types of whole tumor antigens that we could use to pulse 
DCs ex vivo and in vivo. We also discuss the different routes of delivering whole tumor 
antigens to DCs in vivo and activating them with toll-like receptor agonists. 
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1. Introduction 
Whole tumor antigen with its vast amount of characterized and uncharacterized T cell epitopes 
available for activating CD4+ T helper (Th) and CD8+ cytotoxic lymphocytes (CTLs) simultaneously, 
represents an attractive alternative source of antigens to tumor-derived peptides and full-length 
recombinant tumor proteins for dendritic cell (DC)-based immunotherapy [1]. Although it is relatively 
easy to synthesize large quantities of clinical-grade tumor-associated peptides for the clinics, most of the 
identified peptides are human leukocyte antigen (HLA)-A2-restricted which means that mostly  
HLA-A2 positive patients would benefit from this form of treatment. Moreover, the elicited immune 
responses in cancer patients are restricted to the peptide used for immunization and might be insufficient 
for controlling tumor growth. As tumor cells frequently undergo high rates of mutation which could 
result in the loss of a single or multiple antigens, it would be ideal to choose a source of antigen that can 
elicit a broad polyclonal tumor-specific response directed against multiple antigenic epitopes. Whole 
tumor antigen offers this distinct advantage as it allows DCs to process and present numerous tumor 
antigens to stimulate a strong polyclonal T cell response to prevent tumor escape. The stimulated CD4+ 
Th cells could also provide cognate help to CD8+ T cells to generate a more robust anti-tumor immunity 
and long-term memory. Moreover, whole tumor cell lysate treatment is suitable for all cancer patients 
regardless of their HLA type. Whole tumor antigen could be administered alone as whole tumor cell 
lysate, exosomes, whole tumor or tumor stroma RNA, or crude eluted tumor-associated peptides to target 
DCs in vivo or pulsed onto DCs ex vivo and subsequently administrated to patients. DC-based 
immunotherapy offers an exciting opportunity for specific targeting of cancers. DCs are essentially the 
master regulators of immune responses, and they are the most potent antigen-presenting cell (APC) 
population for priming and activating naïve T cells to recognize and combat tumors. DCs are 
heterogeneous and different subsets of DCs could be targeted for tumor immunotherapy based on their 
unique toll-like receptor (TLR) expressions. Here, we describe the different types of whole tumor 
antigens available for pulsing DCs ex vivo and in vivo, and we discuss the routes of administering whole 
tumor antigen to DCs and activating them with TLR agonists in vivo. 
2. Types of Whole Tumor Antigens 
2.1. Whole Tumor Cell Lysates 
Results from a meta-analysis of about 1,800 patients showed that patients who were immunized with 
whole tumor vaccines had a significantly higher objective response (8.1%) than patients who were 
immunized with defined tumor antigens (3.6%) [2]. These results provide a strong rationale for using 
whole tumor cell lysate for cancer vaccination. Both autologous and allogeneic whole tumor cell lysates 
can be used for immunizing patients. Allogeneic tumor cell lines that share one or more tumor antigens 
as autologous tumor cells can be processed easily in large quantities and stored as “off-the-shelf” vaccines. 
A tumor vaccine that is composed of three irradiated allogeneic melanoma cell lines demonstrated promising 
results in a phase II clinical trial but was terminated in a phase III study due to low efficacy [3,4]. Another 
example is the Prostate GVAX vaccine, which consists of allogeneic prostate tumor cell lines LNCaP 
and PC-3 modified by adenovirus to secrete granulocyte-macrophage colony-stimulating factor  
(GM-CSF) to enhance the recruitment of DCs to the vaccination site. It has been tested in patients with 
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hormone-refractory prostate cancer (HRPC) in many phase I/II studies. The Prostate GVAX vaccine 
which demonstrated encouraging results was irradiated before intradermal administration [5–7]. In a 
multicenter trial, 34 of 55 patients with metastatic HRPC treated with Prostate GVAX showed an 
improved overall median survival of 26 months compared to patients who received taxane chemotherapy 
alone [8–10]. The GVAX approach was also being tested with autologous tumor cells in several phase I 
clinical trials for stage IV melanoma, advanced ovarian cancer, non-small cell lung cancer, renal cancer 
and acute myleogenous leukemia. Tumor-infiltrating lymphocytes (TILs) with CTL activity and 
humoral responses were detected in some of the treated subjects [11–14], and approximately 20% of the 
subjects showed a long-term survival of more than five years [15]. Similarly, irradiated autologous whole 
tumor lysate could be administered in combination with recombinant GM-CSF to cancer patients. Powell 
and colleagues immunized 22 mesothelioma patients with this treatment method and showed that seven 
patients developed anti-tumor responses. The treatment was well tolerated with no toxicity, and the 
median survival of all the patients was 11.5 months. The one- and two-year survival rates were 50% and 
27%, respectively [16]. The use of autologous tumor cells is more applicable than allogeneic tumor cell 
lines as it is a completely personalized approach where the unique array of mutated tumor antigens in 
each patient could be essential for tumor-rejection responses. Recent data demonstrate that tumor antigens 
resulting from somatic mutations or epigenetic deregulations are rarely shared among different tumors and 
actually exhibit an extreme degree of heterogeneity. For example, in ovarian carcinoma, the Cancer Genome 
Atlas’s (TCGA) data demonstrated an average of 60 private, non-synonymous mutations per tumor [17], 
thus warranting the personalized whole tumor lysate vaccine approach. 
2.2. Approaches to Preparing Whole Tumor Cell Lysate Vaccines 
Whole tumor cell lysates can be prepared by ultraviolet B (UVB) ray-irradiation or repeat cycles of 
freezing and thawing, which are the two most commonly used methods in the clinic. Tumor cells that are 
subjected to UVB-irradiation will undergo apoptosis leading to the exposure of phosphatyidylserine (PS) 
on the tumor cell surface to facilitate uptake and cross-presentation by DCs [18–20]. During cellular 
apoptosis, calreticulin (CRT) which is a Ca2+-binding protein in the endoplasmic reticulum would 
translocate to the tumor cell surface to act as a crucial determinant for phagocytosis by DCs and 
macrophages [21]. In addition, high mobility group box 1 [HMGB1] [22,23] and pentraxin-3 [PTX3] [24] 
are released by late-stage apoptotic cells to stimulate DC maturation and modulate immune  
responses [25]. Necrosis, for example, as induced by a repeated freeze-thaw process, causes tumor cells 
to release HMGB1 as well as other cellular components such as heat shock proteins (HSP) 70 and 90, 
mitochondria, cellular membrane, RNA, DNA and uric acid. DCs have been shown to undergo partial 
maturation upon interaction with necrotic tumor cells [26]. One possible mechanism is via the 
recognition of HSP [27] and HMBG-1 [28] by scavenger receptor-A and TLR4 on DCs, and another 
mechanism is through interaction with uric acid which is the natural end product of the purine metabolic 
pathway of degraded cellular RNAs and DNAs [29,30]. Hyperthermia, which is the heating of tumor 
cells, is also a potential method for increasing the immunogenicity (reviewed in [31]). Ex vivo heating 
of tumor cells at 39.5 °C for 6 h could be used to increase the surface expressions of MHC class I-related 
chain A (MICA) which is a natural killer group 2D (NKG2D) ligand, thus making tumor cells more 
sensitive to cytolysis by natural killer [NK] cells [32]. Furthermore, the ex vivo heating of tumor cells at 
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42 °C for 30 min enhances their tumor antigen expression leading to better recognition by tumor-specific 
CD8+ T cells [33]. Heating could also upregulate HSPs that have strong immunostimulatory properties. For 
example, HSP70 released from heated tumor cells could bind directly to TLR4 on DCs to activate their 
proinflammatory cytokine production and antigen uptake [34]. 
Live tumor cells are shown to produce immunosuppressive cytokines such as IL-10 and TGF-β to 
hinder anti-tumor T cell responses and promote T regulatory (Treg) cell functions [35]. TGF-β could 
also inhibit DC differentiation [36,37] and NK cell functions [38]. Therefore, a whole tumor lysate 
preparation that simultaneously induces an immunogenic cell death and inactivates immunosuppressive 
cytokine production from the tumor cells would be highly desirable. In a small-scale phase I recurrent 
ovarian cancer clinical trial at the University of Pennsylvania, we used hypochlorous acid (HOCl) to 
induce primary necrosis in the tumor cells as well as increase their immunogenicity for DC uptake and 
processing [1,39,40]. We optimized this approach in a preclinical mouse ID8 ovarian tumor model by 
comparing the efficacy of DCs loaded with three different whole tumor lysate preparations, i.e.,  
UVB-irradiated tumor lysate, freeze-thawed lysate and HOCl-oxidized whole tumor lysate. We 
demonstrated that mice treated with bone marrow-derived DCs pulsed with HOCl-oxidized whole tumor 
cell lysate of ID8 expressing ovalbumin (ID8-ova) had the best tumor control with >60% cure rate [41]. 
In contrast, mice that were treated with DCs pulsed with freeze-thawed (100%) and UVB-irradiated  
ID8-ova whole tumor cell lysate (70%), succumbed to tumor growth and ascites formation. The 
superiority of HOCl-oxidized whole tumor cell lysate preparation could be attributed to the induction of 
less Treg cells in peripheral blood and absence of serum IL-10 in the vaccinated mice and not in mice 
treated with other UVB-irradiated or freeze-thawed whole tumor lysate preparations. We translated these 
findings into a phase I trial by immunizing patients with autologous DCs loaded with autologous whole 
tumor cell lysate prepared with HOCl-oxidation [41]. Similar to the ID8 mouse ovarian tumor model, 
we observed that patients who demonstrated strong anti-tumor T cell responses also showed less 
peripheral Treg cells and reductions of IL-10 in the sera following immunization. In addition, the 
monocyte-derived DCs loaded with HOCl-oxidized whole tumor cell lysate produced significantly 
higher IL-12 upon stimulation with LPS and IFN-γ compared to monocyte-derived DCs loaded with 
UVB-irradiated or freeze-thawed whole tumor cell lysates. As HOCl-oxidation induces necrotic tumor 
cell death [39], it could also cause the release of numerous danger signals such as DNA, RNA, ATP, uric 
acid, HMGB1, and HSP from the oxidized tumor cells to increase their immunogenicity and to activate 
DCs. In addition, numerous HOCl-oxidized biomolecules including proteins, lipids, and glycoproteins 
could simultaneously engage and activate various scavenger receptors such as LOX-1 [42], CD36, and 
MARCO, and possibly TLRs present on DCs perhaps leading to higher IL-12 secretion from DCs. Our 
group and others have shown that ovarian tumors produced IL-10 and TGF-β [43,44], thus it is 
reasonable to suggest that HOCl-oxidation and not UVB-irradiation or repeat freeze-thaw cycles might 
have helped to inactivate these suppressive cytokines in the whole tumor cell lysate. Figure 1 
demonstrates the current whole tumor lysate preparations used in clinics. 
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Figure 1. Four whole tumor lysate preparations currently in use in the clinics. (A) 
Hypochlorous acid (HOCl) induces rapid necrotic cell death and enhances the immunogenicity 
of tumor proteins via oxidation. The increased immunogenicity of HOCl-oxidized tumor 
proteins are due to a number of mechanisms, including specific binding of oxidized proteins 
to low-density lipprotein (LDL) receptor to activate dendritic cells (DCs), improved degradation 
of oxidized proteins by proteinases, improved DC antigen processing and presentation via 
the major histocompatibility (MHC) molecules, and crosspriming of tumor-specific T cells 
via T cell receptor (TcR). HOCl might also inactivate IL-10 and transforming growth factor 
(TGF)-β that can inhibit anti-tumor responses and facilitate T regulatory (Treg) cell 
proliferation; (B) Ultra-violet B (UVB)-irradiation induces apoptotic tumor cell death. This 
causes the exposure of phosphatidylserine (PS) and translocation of calreticulin (CRT) to 
facilitate DC uptake and crosspresentation of the apoptotic tumor cells. The release of high 
mobility box group-1 (HMGB-1) and pentraxin-3 (PTX-3) by late-stage apoptotic tumor 
cells can stimulate DC maturation and elicit specific anti-tumor T cell responses; (C) Repeated 
freeze-thaw treatment of tumor cells induces necrotic cell death and cause the release of 
numerous danger signals such as HMGB-1, heat-shock proteins (HSPs), DNA, RNA and 
uric acid that stimulate partial DC maturation. Danger signals such as HSPs, HMGB-1 and 
uric acid could bind to scavenger receptor-A and toll-like receptor (TLR) 4 on DCs to elicit 
immune responses; (D) Hyperthermia, which is heat-kill treatment of tumor cells, induces 
necrotic cell death and increased expression of MICA (major histocompatibility class I 
chain-related; natural killer group 2D [NKG2D] ligand) and MHC Class I to improved 
natural killer (NK) cell and antigen-specific CD8+ T cell recognition, respectively. 
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Whole tumor cells can be genetically modified to produce cytokines to enhance the stimulation of 
anti-tumor response or to inhibit tumor cell production of immunosuppressive cytokines such as TGF-β. 
Senzer and colleagues recently described a novel FANG vaccine whereby autologous whole tumor cells 
are being genetically engineered to express GM-CSF via a plasmid and a bifunctional short hairpin RNAi 
(bi-shRNAi) to target furin convertase to downregulate endogenous TGF-β1 and -β2 [45]. Forty-two 
patients with advanced cancer received the FANG vaccine intradermally at a dose of 1 × 107 or  
2.5 × 107 cells/mL injection once a month for a total of 12 months. The vaccine was well tolerated and 
only grade 1–2 adverse events such as local induration (n = 14) and erythema (n = 11) were observed. 
Tumor-specific responses were detected four months after the last vaccination in 9 out of 18 patients and 
they positively correlated with the duration of patient’s survival from the time of vaccination (p = 0.025). 
Based on these promising results, a phase II trial with the FANG vaccine is currently being planned. 
Downregulating TGF-β and increasing GM-CSF secretion would help to enhance the recruitment of 
DCs and increase the activation of NK cells and tumor-specific T cells. Similarly, autologous whole 
tumor cells could be transduced with the CD86 (B-7) molecule to increase the priming of anti-tumor T 
cell responses. Such CD86-expressing irradiated autologous tumor cell vaccines have been evaluated in 
combination with subcutaneous IL-2 administration in a phase II study involving 66 stage IV renal cell 
carcinoma patients [46]. These patients received three subcutaneous tumor cell vaccine injections at four-
week intervals followed by subcutaneous IL-2 treatment for six weeks starting at week 7. The rationale 
was to costimulate tumor-reactive T cells with CD86 before IL-2 exposure. It was found that 3% of the 
patients experienced complete responses, 5% had partial responses, 64% showed stable diseases, and 
28% had disease progression after treatment. The median survival of these patients was 21.8 months 
(95% confidence interval 17.8 to 29.6). Moreover, longer median survival was observed in patients 
whose biopsies showed lymphocytic infiltration compared to patients whose biopsies lacked such 
infiltration (28.4 versus 17.8 months, p = 0.045, two-sided log-rank test, post-hoc comparison). 
2.3. Exosomes Derived from Tumor Cells 
In normal physiological and pathological conditions, almost all cell types including DCs produce 
exosomes in their multivesicular endosomes, which are subsequently secreted via exocytosis into the 
extracellular environment. Abundant tumor-derived exosomes are present in the plasma, ascites and 
pleural effusions of cancer patients, and they resemble miniatures of the host tumor cells by containing 
a host of tumor-associated antigens such as HER-2/neu, EGFR2, CEA, MART-1, gp100, TRP-1, 
mesothelin, and members of the HSP family including HSP 70 and HSP 90 [47–50]. Interestingly,  
tumor-derived exosomes obtained from stressed tumor cells are shown to be highly immunogenic [51,52], 
possibly due to the enrichment of danger signals such as uric acid and HMGB1 in the vesicles under 
stress condition. It could be envisioned that an approach to introduce stress, e.g., HOCl-oxidation, UVB-
irradiation or hyperthermia as described earlier, could be used to prepare exosomes from treated tumor 
cells for loading DCs in vivo. On the other hand, increasing evidences suggest that tumor-derived 
exosomes could suppress T cell by inducing apoptosis in vitro through membrane-bound CD95 ligand 
(FasL) [53] or galectin 9 [54]. Membrane-bound TGF-β on tumor-derived exosomes could also inhibit 
IL-2 induced T cell proliferation and promote Treg cell function [55]. Furthermore, tumor exosomes 
could reduce the cytotoxic capacity of NK cells by downregulating NKG2D [56], impairing the 
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differentiation of myeloid precursors into DCs [57], and inducing the generation of myeloid-derived 
suppressor cells [MDSC] [58]. Tumor-derived exosomes represent an attractive cell-free approach to 
tumor immunotherapy; however, careful optimization is required to harness their immunostimulatory 
capability while avoiding the suppressive effects. The use of autologous ascites-derived exosomes (Aex) 
has been explored in a phase I colorectal cancer clinical trial whereby 40 advanced stage patients were 
vaccinated subcutaneously once a week for a total of four weeks with Aex alone or in combination with 
recombinant GM-CSF [59]. The exosomes were found to contain diverse immunomodulatory markers 
and carcinoembryonic antigen (CEA), which was expressed by all the patients in the study. Aex 
vaccination was found to be feasible, safe and well tolerated, and patients who received Aex with  
GM-CSF but not Aex alone showed a beneficial tumor-specific CTL response. In the meantime, more 
clinical trials are needed to determine if this approach is applicable to other cancer types, and whether 
the use of exosomes derived directly from tumor cells will also elicit beneficial anti-tumor response. 
2.4. Tumor Cell-Derived Messenger Ribonucleic Acid 
Immunizing cancer subjects with ribonucleic acid (RNA) derived from autologous tumor cells is a 
promising immunotherapeutic approach. RNAs offer similar advantages as the whole tumor cell lysate; 
this form of therapy has no HLA-restriction, multiple tumor-associated antigens can be targeted at the 
same time, and both CD4+ and CD8+ T cell responses can be elicited via DCs. Most importantly, RNAs 
can be used when obtaining a large number of tumor cells for creating a whole tumor cell lysate vaccine 
is prohibitive. Another advantage of RNA is that one can also obtain antigens associated with tumor 
stroma as increasing evidence now points to the immunomodulatory effects of tumor stroma on  
anti-tumor responses [60]. RNA are also easily degraded and cleared quickly out of the organism to 
minimize the chance of causing side effects such as autoimmune disease or generation of autoantibodies. 
Furthermore, the administration of RNAs is relatively easy as they only need to gain access to the cell 
cytoplasm as opposed to the cell nucleus by naked DNA. Moreover, large amounts of RNA can be 
prepared ex vivo by generating complete tumor cDNA libraries with polymerase chain reaction (PCR) 
technology [61,62]. One major disadvantage of RNAs is that they are intrinsically unstable, and careful 
handling of tumor samples and extracted RNAs is required right from the initial biopsy excision. Due to 
the technical challenges relating to the handling of RNA to avoid degradation, no clinical trial has been 
published to our knowledge that described the direct administration of tumor-derived RNAs in patients 
to target DCs in vivo. 
Alternatively, electroporation can be used to introduce mRNA rapidly into DCs ex vivo to protect 
against rapid degradation. When modified ex vivo, DCs can be made to express, process and present 
specific tumor antigens to a high level to help elicit a higher avidity tumor-specific T cell response.  
A number of clinical trials have reported vaccination of cancer patients with DCs that are transfected 
with tumor RNA (reviewed in [63]). In a phase I trial, autologous DCs were transfected with total renal 
tumor cell RNA by electroporation to treat 10 patients with metastatic renal cell carcinoma [64]. In this 
trial, the use of mRNA represents the entire spectrum of tumor-associated antigens that could help in 
generating a polyclonal tumor response. In 6 of the 7 evaluable patients, the modified DC vaccine elicited 
a broad-based anti-tumor response directed against many tumor antigens including hTERT, G250 and 
oncofetal antigen, but not against self-proteins that are expressed by normal renal tissues. It was also 
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noted that 7 out of 10 patients showed a prolonged mean overall follow-up of 19.8 months. In another 
phase I/II trial, 22 patients with advanced melanoma were vaccinated with monocyte-derived autologous 
DCs that were transfected with autologous whole tumor mRNA [65]. Antigen-specific T cell proliferation 
and IFN-γ responses were detected in 9 out of the 19 evaluable patients, while 10 out of 22 patients 
experienced delayed-type hypersensitivity (DTH) reaction. In a glioblastoma study, patients were  
treated with autologous monocyte-derived DCs electroporated with the whole mRNA of glioblastoma  
cancer stem cells [66]. No adverse side effects were observed in the patients following treatment. T cells 
specific to hTERT- or survivin-derived peptides were detected in all the 7 treated patients, while the 
progression-free survival was 2.9 times longer in vaccinated patients (median 694 vs. 236 days,  
p = 0.0018, log-rank test) than in control patients. 
2.5. Personalized Mutanome-Based Vaccines 
The cancer mutanome, which refers to an individual patient’s tumor-specific mutations and 
alterations that result in the generation of neo-tumor antigens, can potentially be exploited to treat cancer 
patients in a highly personalized manner. It has been demonstrated that 95% of the mutations in a 
patient’s tumor appeared to be unique and only a small number of mutations are shared between  
patients [67]. It has been suggested that such mutanome-encoded antigens may evoke a more vigorous 
T cell response than shared tumor antigens due to a lack of thymic tolerance against them. Moreover, 
mutanome-encoded antigens are restricted to the tumors that express the mutated antigens [68]. The 
rapid advancement of next-generation sequencing technologies and bioinformatics allow for rapid and 
affordable interrogation of patients’ genome, exome, epigenome and transcriptome at the single 
nucleotide level. Indeed, genome-wide mutation identification initiatives have been launched which 
include the Cancer Genome Association and the International Cancer Genome Consortium to map  
every patient’s individual tumor mutanome “signature.” This should help in identifying important tumor 
cell targets. 
One potential method of immunizing cancer patients with mutanome-based vaccines is through the 
administration of coding mRNAs that have been synthesized to encode for multiple types of mutated 
tumor transcripts [69]. This approach has several advantages as we could customize the mRNAs to 
increase their therapeutic value by selecting the sequences that encode for highly immunogeneic mutated 
tumor antigens. Other potential approaches include the use of directly eluted tumor-associated peptides 
from the tumor cell surface and circulating tumor-derived HLA-peptide complexes [70]. Using the 
murine B16.F10 melanoma cell line for cancer mutanome analysis, Castle and colleagues sequenced the 
protein-coding genome (i.e., the exome) of B16.F10 cells and of C57BL/6 wild-type mouse cells [71,72].  
It was found that of the 50 confirmed expressed non-synonymous mutations, one-third of these mutated 
epitopes were as strongly immunogenic as the positive control TRP-2 which is the strongest known 
B16.F10 murine melanoma antigen. Moreover, the induced T cell response was specific to the mutated 
epitopes and not to the respective wild types [73]. Similarly, Robbins and colleagues evaluated three 
melanoma patients who responded to the treatment with ex vivo expanded autologous tumor-infiltrating 
lymphocytes (TILs), and discovered a total of seven unique mutanome-derived tumor peptides that were 
presented by autologous tumor cells and recognized by the autologous TILs [74]. In a clinical study, nearly 
50% of the patients with vulvar intraepithelial neoplasia experienced complete remissions after treatment 
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with neo-epitopes of human papilloma virus (HPV) E6 and E7 peptides [75]. Moreover, several clinical 
studies have tested mutated epitopes or individually expressed mutations as vaccine targets [76–78] and 
demonstrated that mutated epitopes could elicit immune responses in the immunized patients [79] and 
could act as tumor-rejection antigens in mouse tumor models [80]. In the case of advanced melanoma, 
it has been shown that the induction of a poly-epitopic tumor-specific immune responses by autologous 
patient-specific vaccines correlated with complete remissions [81]. Thus, interrogating the cancer 
mutanome would potentially provide numerous targets for poly-epitope vaccine development in each 
individual patient. Phase I clinical trials have been initiated to test mutanome-derived tumor peptides in 
glioblastoma (ClinicalTrial.gov: NCT02287428) and melanoma (NCT01970358, NCT02035956). A 
summary of vaccine studies utilizing whole tumor antigen in preclinical animal models and in the context 
of clinical trials are summarized in Table 1 and 2 respectively. 
2.6. Tumor Stroma-Associated Antigens 
Besides targeting tumor cells directly, increasing attention has been given to target the tumor stroma 
where heterogeneous populations such as fibroblasts, endothelial cells, T reg cells, tumor-derived 
macrophages (TAMs), MDSCs, as well as extracellular matrix could be found. Together, they help to 
create a highly immunosuppressive tumor microenvironment for tumorigenesis, progression and 
metastasis. Unlike tumor cells that exhibit high rates of somatic mutations, tumor stroma cells are 
genetically more stable thus making them attractive targets for tumor-specific T cells to induce long-term 
tumor control. Moreover, tumor cells could employ numerous evasion mechanisms, e.g., defects in their 
antigen-presentation pathways due to loss of MHC class I heavy chains, β2-microglobulin and/or tapasin 
expression, to prevent tumor-specific CTL recognition. Tumor stroma cells, on the other hand, are less 
subjected to such immune evasion mechanisms. 
Tumor stroma cells are shown to be different from their normal counterparts owing to their 
upregulation of certain tumor stroma-associated antigens (TSAAs) under the influence of the tumor 
microenvironment. The cancer-associated fibroblasts (CAFs), being the most abundant cell type in the 
stroma, could serve as useful targets as they are involved in multifaceted functions such as remodeling 
the tumor extracellular matrix, suppressing anti-tumor immune responses, and secreting growth factors 
and cytokines that promote tumor growth, invasion, differentiation, angiogenesis, and chronic inflammation 
(reviewed in [82]). CAFs overexpressed fibroblast activation protein α (FAPα; seprase) which is a 
surface glycoprotein that is only induced during carcinogenesis in numerous solid tumors [83–85].  
Its overexpression is associated with increased tumor growth, invasion, angiogenesis, metastasis [86,87], 
and reduced survival in patients with FAPα+ gastric carcinoma [83]. In addition, the matrix 
metalloproteinases (MMPs) and their inhibitors are TSAAs that are expressed by CAFs, endothelial 
cells, TAMs and tumor cells. They are overexpressed in neoplasia and are critical modulators of the 
extracellular matrix composition. 
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Table 1. Evaluation of different whole tumor antigens in selected preclinical mouse tumor models. 
Source of Whole  
Tumor Antigen 
Method of Whole Tumor 
Antigen Preparation 
Treatment Regimen Outcome of Study Reference 
Whole mouse 
glioblastoma cell lysate 
Freeze-thawed whole tumor lysate 
administered alone or in 
combination with type B  
CpG (ODN 1826) 
Glioblastoma-bearing mice were 
immunized subcutaneously with the 
tumor lysate-CpG vaccine 
 Significantly more T cells and activated DCs were 
observed in lymph nodes draining the vaccination site 
of mice that were treated with lysate-CpG when 
compared to mice treated with CpG or tumor lysate 
alone (p < 0.05) 
 55% of the mice vaccinated with CpG-lysate vaccine 
tumor-free and showed 2 times greater median survival 
than mice that were treated with CpG only, tumor lysate 
only or no treatment (p < 0.05) 
[88] 
Whole fibrosarcomas or 
mammary carcinoma 
cell lysate 
Freeze-thawed whole tumor cell 
lysate was pulsed onto mouse bone 
marrow-derived DCs 
Fibrosarcomas or mammary 
carcinoma-bearing mice were 
vaccinated subcutaneously with the 
whole tumor lysate-DC vaccine 
 Both CD8+ and CD4+ tumor-specific T cells were 
induced following vaccination that contributed to  
tumor suppression 
 Significant reductions in the number of lung metastases 
were observed in mice treated with the whole tumor 
lysate-DC vaccine when compared to mice treated with 
tumor lysate alone, unpulsed DC alone or untreated 
[89] 
Whole ovarian 
carcinoma cell lysate 
Whole tumor cells were oxidized 
with HOCl and then frozen and 
thawed, and pulsed onto mouse 
bone marrow-derived DCs  
(i.e., mouse OCDC vaccine) 
Ovarian carcinoma-bearing mice  
were treated intradermally with  
OCDC vaccine 
 Mice treated with OCDC had the best tumor control 
with >60% cure rate, while 100% and 70% of the mice 
treated with DCs pulsed with freeze-thawed or  
UVB-irradiated lysate succumbed to tumor growth  
and ascites 
 Less peripheral Treg cells and absence of serum IL-10 
were observed in mice treated with OCDC vaccine 
when compared to mice treated with DC vaccine pulsed 
with UVB-irradiated or freeze-thawed tumor lysate 
[41] 
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Table 1. Cont. 
Source of Whole  
Tumor Antigen 
Method of Whole Tumor 
Antigen Preparation 
Treatment Regimen Outcome of Study Reference 
Whole ovarian tumor 
cells expressing HPV 
E6 and E7 
UVB-irradiated whole cells  
pulsed onto mouse bone  
marrow-derived DCs 
Ovarian carcinoma-bearing mice  
were treated intraperitoneally  
and subcutaneously with the  
UVB-irradiated tumor cell-DC vaccine 
 E6- and E7-specific IFN-γ secreting T cells were 
elicited that infiltrated the tumor and helped suppressed 
tumor growth 
[90] 
Total RNA of whole 
ovarian tumor cells 
expressing HPV E6  
and E7 
Total tumor RNA was 
electroporated into mouse  
bone marrow-derived DCs 
Ovarian cancer-bearing mice were 
vaccinated with DCs electroporated 
with total tumor mRNA via the 
intraperitoneal and  
subcutaneous routes 
 It was found that DCs loaded with total tumor RNA 
elicited a significantly higher IFN-γ secreting E6- and 
E7-specific T cells than DCs loaded with  
UVB-irradiated whole tumor cells in the mice 
 DCs electroporated with total tumor RNA also induced 
a larger tumor infiltration by T cells and produced a 
significantly stronger delay in tumor growth when 
compared to DCs pulsed with UV-irradiated tumor cells 
[90] 
Mutanome peptides of 
mouse melanoma cells 
Mutated epitopes of  
tyrosinase-related protein 2  
(TRP-2) were identified via 
sequencing the protein-coding 
genome of the B16.F10 mouse 
melanoma cells 
Melanome-bearing mice were 
immunized subcutaneously with the 
long mutanome peptides and  
Poly(I:C) as adjuvant 
 A total of 50 validated mutations were found to be 
immunogenic following immunization of the mutated 
epitopes in the mice 
 Melanoma-bearing mice immunized with the mutated 
peptides successfully controlled tumor growth 
[73] 
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Table 2. Evaluation of different whole tumor antigens in selected published clinical trials. 
Source of Whole 
Tumor Antigen 
Method of Whole Tumor 
Antigen Preparation 
Treatment Regimen Outcome of Study Reference 
Autologous whole 
ovarian tumor cells 
Whole tumor cells were 
modified with dinitrophenyl 
(DNP) and UVB-irradiated 
Phase I trial in stage III ovarian cancer where 
patients were immunized intradermally with  
the vaccine 
 No acute toxicities. 
 Anti-tumor responses were demonstrated in 
some patients but no clinically meaningful 
responses were observed. 
[91] 
Autologous whole 
melanoma cells 
Whole tumor cells  
were UVB-irradiated 
Phase III/IV metastatic melanoma trial where 
patients were vaccinated intradermally with 
UVB-irradiated autologous whole cells and 
Bacillus Calmette-Guérin (BCG) as adjuvant 
 5-year overall patient survival rate was  
~45% which was superior to historical 
controls (at 35% and 20% for Stage III  
and IV, respectively). 
[92] 
Allogeneic melanoma 
cell lysate derived from 
3 different melanoma 
lines (TRIMEL) 
TRIMEL was subjected to 
freeze-thawed cycles and 
pulsed on autologous 
monocyte-derived DCs  
(i.e., TRMEL-DC vaccine) 
Phase I trial where stage IV and III melanoma 
patients were vaccinated intradermally with 
TRIMEL-DC vaccine and aluminum  
hydroxide/keyhole limpet haemocyanin (KLH) 
as an adjuvant 
 >60% of the stage IV patients experienced 
positive DTH reaction after treatment 
 Median survival of these patients was  
33 months compared to 11 months for  
stage IV patients without DTH response. 
 All stage III patients were DTH-positive  
after vaccination and remained tumor-free  
for a median follow-up period of 48 months 
(range of 33 to 64 months) 
[93] 
Allogeneic whole 
prostate tumor cells 
Prostate tumor cell lines 
LNCaP and PC-3 were 
genetically modified to  
secrete GM-CSF (i.e., GVAX 
vaccine) and UVB-irradiated 
Phase I/II studies in metastatic  
hormone-refractory prostate cancer (HRPC) 
whereby patients were immunized intradermally 
with GVAX vaccine 
 In the largest of these multicenter trials, 34 of 
55 HRPC patients demonstrated an improved 
overall median survival of 26 months that 
compared favorably with the median survival 
observed in similar HRPC patients in phase II 
taxane chemotherapy trials 
[5–7] 
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Table 2. Cont. 
Source of Whole 
Tumor Antigen 
Method of Whole Tumor 
Antigen Preparation 
Treatment Regimen Outcome of Study Reference 
Autologous whole 
mesothelioma  
tumor cells 
Autologous tumor cell lysate 
was administered with 
recombinant GM-CSF 
Phase I trial of mesothelioma patients who were 
vaccinated subcutaneously with whole tumor 
lysate vaccine and recombinant GM-CSF 
 Antitumor immune response and was detected 
in 7 out of 22 immunized patients. 
 The median survival of all the patients was 
11.5 months. 
 1- and 2-year survival rates were 50%  
and 27%, respectively. 
[16] 
Autologous whole 
ovarian tumor  
cell lysate 
Whole tumor cells were 
oxidized with HOCl and  
then frozen and thawed,  
and pulsed on autologous 
monocyte-derived DCs  
(i.e., OCDC vaccine) 
Phase I trial of recurrent ovarian cancer 
whereby patients were vaccinated intranodally 
with OCDC vaccine 
 Induction of tumor-specific IFN-γ T cell 
responses, and reductions of peripheral  
Tregs and serum IL-10 observed in 4 out of 
the 5 immunized patients 
 2 out 5 immunized patients achieved 
prolonged progression-free survival of  
over 2 years 
[41] 
Autologous  
Ascites-derived 
exosomes (Aex) from 
colorectal tumor cells 
Aex administered alone or  
in combination with 
recombinant GM-CSF 
Phase I colorectal cancer whereby advanced 
stage patients are vaccinated subcutaneously 
with Aex ± recombinant GM-CSF. 
 Aex vaccination was found to be safe and 
well tolerated 
 Beneficial tumor-specific CTL response was 
observed in patients who received Aex with 
GM-CSF but not Aex alone 
[59] 
Total mRNA derived 
from renal tumor cells 
Total tumor mRNA was used 
to transfect autologous 
monocyte-derived DCs 
Phase I trial of metastatic renal cell carcinoma 
where patients were vaccinated intravenously 
with the tumor mRNA-expressing DCs 
 Polyclonal anti-tumor response directed 
against many tumor antigens including 
hTERT, G250, and oncofetal antigen were 
detected in 6 of the 7 evaluable patients 
following immunization with the total  
tumor mRNA-expressing DCs 
 7 out of 10 immunized patients showed a 
prolonged mean overall follow-up of  
19.8 months 
[64] 
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Table 2. Cont. 
Source of Whole 
Tumor Antigen 
Method of Whole Tumor 
Antigen Preparation 
Treatment Regimen Outcome of Study Reference 
Total mRNA derived 
from melanoma cells 
Total tumor mRNA was used 
to transfect autologous 
monocyte-derived DCs 
Phase I/II trial of advanced melanoma where 
patients were vaccinated intradermally or 
intranodally with the tumor mRNA-expressing 
DCs. No serious adverse effects were observed. 
 A vaccine-specific IFN-γ response was 
demonstrated in 9 out of 19 evaluable patients 
 7 out of 10 patients vaccinated intradermally 
showed DTH reaction, while 3 out of  
12 patients vaccinated intranodally had  
DTH reaction 
[65] 
Total mRNA derived 
from glioblastoma 
cancer stem cells 
Total mRNA from cancer 
stem cells was electroporated 
into autologous  
monocyte-derived DCs 
Phase I trial where patients were  
treated intradermally with autologous 
monocyte-derived DCs that were  
electroporated with the total mRNA of 
glioblastoma cancer stem cells 
 T cells specific to hTERT or survivin were 
detected to all the 7 treated patients 
 Progression-free survival was 2.9 times 
longer in vaccinated patients (median 694 vs. 
236 days, p = 0.0018, log-rank test) than in 
control patients 
[66] 
Mutanome peptides 
derived from E6 and 
E7 of HPV 
Synthetic long peptides 
administered in incomplete 
Freund’s adjuvant 
Phase I study where patients with vulvar 
intraepithelial neoplasia were treated 
subcutaneously with the E6 and E7  
mutanome peptides 
 85% of the immunized patients developed  
T cells that were specific for E6, E7, or both 
 ~50% of the patients experienced  
complete remissions after treatment  
with E6 and E7 neo-epitopes 
[75] 
Mutanome peptides 
derived from von 
Hippel-Lindau (VHL) 
gene mutations in renal 
cell carcinoma 
Synthetic neo-peptides 
derived from Hippel-Lindau 
(VHL) gene mutations in RCC 
Pilot clinical trial whereby patients with 
advanced RCC and mutated VHL genes were 
vaccinated subcutaneously with the relevant 
VHL peptide mixed with Montanide 
 The vaccine was well tolerated with no  
grade III or IV toxicities observed 
 Four out of five evaluable patients showed 
specific immune responses against the 
corresponding mutant VHL peptides 
 Median overall survival and median 
progression-free survival of the patients  
were 30.5 and 6.5 months, respectively 
[79] 
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Endothelial cells of the tumor stroma have been shown to overexpress a set of tumor endothelial 
markers (TEMs), such as TEM1 and TEM8, during tumor angiogenesis [94]. Although TEM1 mRNA 
is ubiquitously expressed on normal human endothelial cells, the TEM1 protein is restricted to the corpus 
luteum and tissues of healing wounds and tumors. TEM8 protein, on the other hand, is undetectable 
during wound healing or in the corpus luteum [94,95] but is highly expressed in the endothelial cells of 
breast, esophagus, lung, and bladder cancer stroma [96]. Prostate-specific membrane antigen (PSMA) is 
another endothelial cell surface molecule that is upregulated on prostate tumor cells as well as on tumor 
endothelial cells of the stroma of breast, renal cell, bladder, non-small cell lung, prostate and rectal 
carcinoma, glioblastoma multiforme and melanoma [97]. We envisaged that whole lysate or whole RNA 
of tumor stroma could be prepared in a similar manner as with tumor cells, and be administered directly 
to patients or pulsed onto DCs to elicit therapeutic responses against the characterized as well as 
uncharacterized TSAAs. Tumor stroma could also be targeted by adoptively transferred effector T cells 
that recognize tumor antigen-loaded stromal cells. This approach has been tested in a preclinical mouse 
tumor model and resulted in the killing of stromal CD11b+/Gr1+ myeloid cells as well as inhibiting long-
term tumor growth. Thus, targeting both the tumor cells and tumor stroma could be an effective approach 
to eradicate established tumors. As certain TSAAs are expressed by a broad spectrum of solid tumors, 
we could develop tumor stroma-based therapies that are applicable to many cancer types. 
3. Factors Influencing the Immune Responses to Whole Tumor Antigens 
3.1. Immunodominant Antigens versus Mutated Neo-Antigens for Vaccination 
The identification of tumor-associated antigens (TAAs) with early technology such as SEREX 
(serological analysis of autologous tumor antigens in serum of cancer patients by recombinant cDNA 
expression cloning), has allowed us to classify TAAs into five broad categories: (1) mutated antigens 
only expressed by the tumors; (2) overexpressed normal self-antigens; (3) oncofetal antigens as those 
expressed in fetal tissues; (4) differentiation or lineage antigens; and (5) cancer-testis antigens that are 
also expressed by spermatocytes/spermatogonia. Many of the current whole tumor antigen vaccines, 
whether with allogeneic or autologous tumor as the starting material, are developed based on the 
knowledge of the human immune system’s ability to recognize immunodominant antigens (i.e., antigens 
that are most easily recognized by the immune system to elicit antigen-specific T cell and antibody 
responses. However, only a small number of patients to date have achieved tumor regressions with whole 
tumor vaccines containing immunodominant antigens. As many of the immunodominant tumor antigens 
are self-proteins, they are subjected to both central and peripheral tolerances that dampen the elicited 
immune responses to avoid autoimmunity. Ironically, it is through the use of highly immunogenic cancer 
vaccine and robust immunization regimen (such as the inclusion of T cell checkpoint blockade and/or 
anti-angiogenesis) that we can break self-tolerance to achieve tumor control and suppression. As 
discussed earlier, the TCGA data revealed that cancers from individual patients showed a high degree 
of unique mutations that are not shared amongst patients who have the same type of cancer. Therefore, 
an attractive alternative is to prepare personalized autologous whole tumor cancer vaccines that contain 
the unique mutated neo-tumor antigens of each individual patient (e.g., mutanome-based vaccines). As 
mutated neo-antigens are presumably not subjected to central tolerance, the elicited immune responses 
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might be more potent than that generated against immunodominant antigens. In addition, these mutated 
antigens are uniquely expressed by the tumors and therefore should not induce toxicity to the normal 
tissues. Although there is a possibility that vaccination with a multivalent vaccine (whether containing 
immunodominant or mutated neo-tumor antigens) could lead to unexpected immunodomination of a 
single or few antigens, there is still a strong rationale to immunize patients with a multivalent whole 
tumor cancer vaccine as opposed to single antigen vaccine to target multiple tumor antigens in parallel 
to prevent tumor escape. One study demonstrated that the numbers of APC such as DCs available for 
presenting the tumor antigens and IL-12 could help modulate the immunodominance of certain tumor 
antigens [98]. These factors could be taken into account when designing a DC-based immunotherapy 
with whole tumor antigen vaccine. 
3.2. Immune Status of Cancer Patients 
The immune status of cancer patients may influence the magnitude of the elicited immune responses 
to whole tumor antigen vaccine. Nevertheless, most of the subjects who are enrolled in cancer clinical 
trials are elderly patients who have significantly compromised immune systems specifically when 
immunosenescence sets in (reviewed in [99]). This is characterized by a lower number of peripheral 
naïve T cells and reduced diversity in the naïve T cell receptor (TCR) repertoire when compared to 
younger individuals [100]. Although there is an increase in the number of memory T cells in the elderly 
population, the diversity and functional integrity of both CD4+ and CD8+ T cells are reduced resulting 
in the inability to respond adequately or to retain memory for cancer antigens expressed by relapsing 
tumors. Certain experimental interventions aiming to boost T cell immunity have been investigated in 
animal models. An example is implanting genetically engineered stromal cells in the thymus to locally 
secrete IL-7, a T cell survival factor [101]. An alternative way is through nutritional interventions. A 
study demonstrated that the use of vitamin E supplement was able to reconstitute immunological synapse 
formation, especially in the naïve CD4+ T cells of old mice [102]. Another study showed that the use of 
conjugated linoleic acid helped to modulate lipid intake leading to decreased proinflammatory cytokine 
secretion thus increasing the success rate of hepatitis B vaccination in elderly people [103]. Importantly, 
the lipid environment could strongly influence T cell function, as well as alter their cell membrane 
fluidity and immunological synapse formation [104,105]. Cancer patients previously treated with 
chemotherapy and/or radiotherapy could also experience a transient compromised immune system due 
to the toxic effects of the treatments to proliferating bone marrow progenitor cells. However, 
accumulating evidence shows that chemotherapy and radiotherapy could also synergize with tumor 
immunotherapy resulting in better efficacies in the patients. For example, 17 patients with advanced 
cancer were immunized with a DNA plasmid vaccine encoding for the tumor antigen CYP1B1 plasmid 
encapsulated in biodegradable poly-DL-lactide-coglycolide microparticles [106]. Five patients who 
developed CYP1B1-specific responses and then received chemotherapy showed a greater and more durable 
response to salvage chemotherapy than similarly treated patients who did not develop CYP1B1-specific 
immunity. These results suggested that patients who were immunized with cancer vaccine previously 
could benefit more from subsequent chemotherapy than those patients who were not immunized. 
Likewise, radiotherapy and tumor immunotherapy could synergize to result in increased efficacies in 
patients [107,108]. 
  
Vaccines 2015, 3 360 
 
 
4. In Vivo Activation of Dendritic Cells (DCs) 
The most widely used DC subset for DC-based immunotherapy in the clinic is the myeloid  
monocyte-derived DC, which is differentiated ex vivo with recombinant GM-CSF and interleukin  
(IL)-4. These DCs are highly efficient in the phagocytosis of antigens and production of high IL-12 upon 
activation. Although they have been used successfully for treating cancers, there are disadvantages and 
advantages associated with using them. The major advantage is that we can easily manipulate them 
before administering them to patients. We can load the DCs with different tumor antigens and activate 
them with a vast array of adjuvants, including TLRs, Montanide and KLH, to express desired phenotypic 
markers and cytokines that will enhance their anti-tumor stimulating capacity [109]. On the other hand, 
one major disadvantage is that the ex vivo production of these DCs is labor intensive and costly. An 
attractive alternative is to specifically target DCs in vivo by loading them with appropriate tumor 
antigens and activating them to produce proinflammatory cytokines to elicit potent anti-tumor T cell 
responses. One major advantage of in vivo targeting is that we can use adjuvants to selectively activate 
one or more DC subsets via their surface receptors to increase the potency of the anti-tumor responses. 
One major disadvantage is that we have less control over the quality and magnitude of the induced  
anti-tumor responses. To successfully target DCs in vivo, we would need to determine the optimal type 
of antigen for loading the DCs, the adjuvant for activating them, and finally the best route of administration. 
Different DC subsets are present in the human immune system, and they follow two major pathways 
of development, i.e., lymphoid-derived pDCs and myeloid-derived conventional DCs that develop from 
CD34+ hematopoietic progenitor cells [110,111]. The myeloid-derived DCs can be further classified into 
different subsets according to their phenotype, receptor expression, chemokine and cytokine production, 
tissue location, and the type of immune response they induce. Such myeloid-derived DCs include the 
Langerhans cells (LCs), dermal DCs (also known as interstitial DCs), and DCs present in the blood and 
lymph nodes. Thus, different DC subsets can be targeted based on their tissue locations and the route of 
tumor antigen administration (e.g., intradermal, intranodal or intratumoral). In addition, we can target and 
activate a specific DC subset via their distinct toll-like receptor (TLR) expressions. Upon TLR 
stimulation, DCs would produce proinflammatory cytokines and chemokines for priming antigen-specific 
T cells. For example, pDCs uniquely expressed TLR7 and 9 and can be activated to become potent 
secretors of IFN-α and -β with Imiquimod and cytosine-phosphateguanine oligodeoxynucleotides 
(CpG), respectively. LCs can be specifically activated via TLR3 with polyribosinic:polyribocytidylic 
acid (Poly I:C), which is a TLR3 agonist. Dermal DCs express TLR4 and can be activated by 
monophosphoryl lipid A (MPLA) which is a chemically modified, less toxic version of the 
lipopolysaccharides (LPS). Lastly, blood and lymph node DCs expressing TLR8 can be targeted with 
VTX-2337 and VTX-297 that are novel small molecules TLR8 agonists developed by VentiRx 
Pharmaceuticals (Seattle, WA, USA). 
5. In Vivo Tumor Antigen Administration: Intradermal, Intranodal and Intratumoral 
Subcutaneous and intramuscular have been the traditional routes for vaccinations against many 
different viral and bacterial diseases. Recent clinical results showed that the intradermal route is more 
effective than the conventional subcutaneous and intramuscular routes in inducing protective immunity 
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against many diseases, including hepatitis B virus (HBV) [112,113], rabies [114], tuberculosis [115], 
measles [116], polio [117] and influenza [118]. Moreover, subjects who are unresponsive to the 
intramuscular route of vaccination for HBV can achieve seroconversion at a lower vaccine dose via 
intradermal vaccination [119]. A similar observation has been made with the rabies vaccine whereby 
subjects receiving a lower dose intradermally achieved a long-lasting antibody response that was 
comparable to subjects receiving a full dose intramuscularly [120]. As the dermis contains a much larger 
DC population compared to the subcutaneous fat and muscles, it is reasonable to postulate that a larger 
number of dermal DCs would take up the antigen and migrate to the draining lymph nodes to prime 
more potent antigen-specific responses. The extensive network of lymphatic vessels found in the dermis 
could also facilitate the migration and interaction between DCs and T cells for stronger T cell priming. 
Furthermore, the increase in the local pressure of the interstitial tissue from the fluid introduced by 
intradermal vaccination could help to increase the lymphatic flow of DC and antigen to the draining 
lymph nodes for presentation to T cells. Finally, intradermal vaccination might be advantageous as  
it favors the drainage of antigen via the lymphatic system in the dermis minimizing the risk of  
systemic shock, which is more likely to occur with intramuscular injections when antigens enter the 
general blood circulation. 
Intranodal administration of tumor antigens into the regional draining lymph nodes is perhaps the 
most straightforward method of ensuring maximum antigen exposure to DCs. It also offers the advantage 
whereby DCs do not need to migrate, as opposed with other routes discussed earlier, for they are already 
in close proximity with T cells in the lymph nodes. LCs and dermal DCs that migrated in the draining 
lymph nodes of the skin can also be pulsed this way. In a mouse study, Kreiter and colleagues 
investigated the different routes of administering antigen-coding mRNA. The authors demonstrated that 
resident DCs in the lymph nodes selectively took up the mRNA following intranodal injection, and 
induced potent antigen-specific CD4+ and CD8+ T cell responses in tumor-bearing mice [71,72]. They 
also showed that potent CTLs and memory T cells were generated in mice via repeated RNA intranodal 
injections, but not via subcutaneous, intradermal or near nodal administrations. The therapeutic efficacy 
of this mRNA could be further enhanced by pre-treating mice with a fusion protein consisting of the 
extracellular domain of human fms-like tyrosine kinase 3 (FLT3) ligand and the heavy chain constant 
regions 2 and 3 (CH2–CH3 domain) of human immunoglobulin (Ig)-G4. The administration of the FLT3 
ligand/IgG4 fusion protein would help in recruiting immature pDCs and enhancing the uptake of the 
antigen-coding mRNA. The approach is currently being tested in a phase I dose escalation trial in 
advanced melanoma with the aim of evaluating the safety and tolerability of intranodal administration 
of tumor antigen-coding mRNA (NCT01684241). We envisage that FLT3 ligand could also be used 
with whole tumor mRNA to increase their uptake by DCs. 
Intratumoral administration of tumor antigens to tumor-infiltrating DCs (TIDCs) and activating them 
might be an alternative option. TIDCs have been documented in a number of cancers including ovarian, 
breast, colorectal, lung, renal cell carcinomas and melanoma [121]; however, their functions have not 
been well characterized. There are some conflicting reports suggesting that immature TIDCs could help 
in promoting tumor growth, while mature TIDCs helped in eliciting antitumor responses [121]. 
Nevertheless, a phase I trial of bladder cancer demonstrated that intravesical infusion of Mycobacterium 
bovis bacillus Calmette-Guérin (BCG) onto the bladder wall promoted longer survival and delayed 
progression of the treated subjects. These effects might be mediated by TIDCs that were activated by 
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infused BCG via their TLR2 [122]. Another phase I trial of recurrent glioblastoma demonstrated that 
subjects who received intracranial administering of CpG showed induction of antitumor responses 
possibly via activated TIDCs [123]. More studies are required to characterize the phenotypes and 
functions of TIDCs, and to determine if they could be activated in vivo with different immunomodulatory 
agonists including TLR agonists. The ability of TIDCs to stimulate a therapeutic antitumor response 
could be highly dependent upon their state of maturation. 
Recently, biodegradable particles have been developed as a mean to effectively deliver antigen and 
activate DCs in vivo. There are different biodegradable particles available ranging from liposomes to 
acid-degradable hydrogels and synthetic polymers. For example, Poly(lactic-co-glycolic acid)  
(PLGA)-encapsulated breast cancer tumor lysate vaccine has demonstrated significant reduction in 
tumor burden when administered subcutaneously to mice [124]. In a prostate cancer mouse model, 
particles co-encapsulating tumor lysate and CpG could induce potent long-lasting CTL responses upon 
subcutaneous administration [125]. Another example is the use of mesoporous silica rods (MSRs) as a 
mean to activate DCs and other immune cells to treat cancers and other diseases. Such MSRs contain 
small holes known as nanopores that can be loaded with cytokines, chemotherapeutic drugs and/or tumor 
antigens to attract and activate specific immune cells [126]. The MSRs can be administered easily via 
injection underneath the skin and spontaneously assemble into a three-dimensional (3D) scaffold at the 
vaccination site. By controlling the types of cytokines released from the MSRs, we could potentially 
manipulate the type of DCs being recruited to the 3D scaffold to initiate an immune response. One 
advantage of MSRs is that they are biodegradable and dissolve naturally within a few months. MSRs 
can also be manufactured easily and rapidly. MSRs have been tested in mice and are found to be effective 
in recruiting millions of DCs to the 3D scaffold before migrating to the lymph nodes and triggering a 
powerful immune response [126]. As demonstrated above, biodegradable particles hold great promise 
for an in vivo vaccination approach and should be investigated further. 
6. Conclusions 
Whole tumor antigens, as opposed to defined tumor-derived peptides and proteins, could represent 
the ideal source for pulsing DCs as they contain a vast array of immunogenic epitopes to activate both 
CD4+ and CD8+ tumor-specific T cells to prevent tumor escape. The use of adjuvants, particularly TLR 
agonists, is a very promising approach to augment DC-whole tumor antigen vaccination. Distinct subsets 
of DCs are present in humans, and they exhibit different phenotypic markers and TLR expressions 
allowing for specific in vivo targeting with different TLR agonists. DCs located at different tissue 
compartments are capable of eliciting different immune responses, thus the selection of DC subset for 
targeting will depend upon the type of immune response desired. 
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